CG Oncology Inc
CGONHealthcare|Biotechnology|USA
$75.24
+1.89 (+2.58%)
Tangible Book
$12.28
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04452591 Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | P3 | Active | 190 | Open-label | Cretostimogene Grenadenorepvec |
| NCT06111235 A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Non Muscle Invasive Bladder Cancer, Urologic Cancer | P3 | Active | 367 | RCT, Open-label | Cretostimogene Grenadenorepvec |
| NCT06567743 Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | High-Risk Non-Muscle-Invasive Bladder Cancer | P2 | Recruiting | 325 | RCT, Open-label | Cretostimogene Grenadenorepvec |
| NCT01438112 Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer | Transitional Cell Carcinoma, Bladder Cancer | P2P3 | Terminated | 22 | RCT, Open-label | CG0070 Adenovirus Vector |
| NCT02143804 Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer | Bladder Cancer, High Grade | P2 | Withdrawn | — | Open-label | oncolytic adenovirus expressing GMCSF |
| NCT02365818 Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure | Bladder Cancer | P2 | Completed | 66 | Open-label | CG0070 |
| NCT04387461 Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin | Non Muscle Invasive Bladder Cancer | P2 | Completed | 35 | Open-label | CG0070, Pembrolizumab Injection |
| NCT04610671 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC | Muscle-Invasive Bladder Carcinoma, Bladder Cancer | P1 | Completed | 21 | Open-label | CG0070, Nivolumab |
| NCT06443944 An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG | Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma | AVAILABLE | — | — | Cretostimogene Grenadenorepvec |